Comparing ligand interactions with multiple receptors via serial docking

Journal of Chemical Information and Computer Sciences

Volumn 44, Issue 6, 2004, Pages 1961-1970

  Fernandes, Miguel X ^a   Kairys, Visvaldas ^a   Gilson, Michael K ^a  

^a UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCKING ALGORITHMS; LIGAND INTERACTIONS; RECEPTORS; SERIAL DOCKING;

ALGORITHMS; DIELECTRIC MATERIALS; MOLECULAR STRUCTURE; PROBLEM SOLVING; SOLVENTS;

LIGAMENTS;

LIGAND; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEINASE INHIBITOR;

ALGORITHM; ARTICLE; CHEMISTRY; COMPUTER SIMULATION; DRUG DESIGN; PROTEIN BINDING; PROTEIN CONFORMATION;

ALGORITHMS; COMPUTER SIMULATION; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; LIGANDS; PROTEASE INHIBITORS; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 10044268555     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci049803m     Document Type: Article

References (58)

1. Vane, J. R.; Bakhle, Y. S.; Botting, R. M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 1998, 38, 97-120.
2. Klabunde, T.; Hessler, G. Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem 2002, 3, 928-944.
3. Shih, C.; Chen, V. J.; Gossett, L. S.; Gates, S. B.; MacKellar, W. C.; Habeck, L. L.; Mendelsohn, K. A. S. L. G.; Soose, D. J.; Patel, V. F.; Andis, S. L.; Rayl, J. R. B. E. A.; Moroson, B. A.; Beardsley, G. P.; Kohler, W.; Ratnam, M.; Schultz, R. M. LY231514, a pyrrolo[2,3d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997, 57, 1116-1123.
4. Lee T.; Laco, G. S.; Torbett, B. E.; Fox, H. S.; Lerner, D. L.; Elder, J. H.; Wong, C. H. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. Proc. Natl. Acad. Sci. 1998, 95, 939-944.
5. Claussen, H.; Bunning, C.; Rarey, M.; Lengauer, T. FlexE: Efficient molecular docking considering protein structure variations. J. Mot. Biol. 2001, 308, 377-395.
6. Knegtel, R. M. A.; Kuntz, I. D.; Oshiro, C. M. Molecular docking to ensembles of proteins. J. Mol. Biol. 1997, 266, 424-440.
7. Osterberg, F.; Morris, G. M.; Sanner, M. F.; Olson, A. J.; Goodsell, D. S. Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins 2002, 46, 34-40.
8. Broughton H. B. A method for including protein flexibility in proteinligand docking: improving tools for database mining and virtual screening. J. Mol. Graph. Model. 2000, 18, 247-257, 302-304.
9. Rockey, W. M.; Elcock, A. H. Progress toward virtual screening for drug side effects. Proteins 2002, 48, 664-671.
10. David, L.; Luo, R.; Gilson, M. K. Ligand-receptor docking with the Mining Minima optimizer. J. Comput.-AidedMol. Des. 2001, 15, 157-171.
11. Kairys, V.; Gilson, M. K. Enhanced docking with the mining minima optimizer: acceleration and side-chain flexibility. J. Comput. Chem. 2002, 23, 1656-1670.
12. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
13. MacKerell, A. D., Jr.; Bashford, D.; Bellott, M.; Dunbrack, R. L., Jr.; Evanseck, J.; Field, M. J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph, D.; Kuchnir, L.; Kuczera, K.; Lau, F. T. K.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D. T.; Prodhom, B.; Reiher, W. E., III; Roux, B.; Schlenkrich, M.; Smith, J.; Stole, R.; Straub, J.; Watanabe, M.; Wiorkiewicz-Kuczera, J.; Yin, D.; Karplus, M. All-atom empirical potential for molecular modeling and dynamics studies of protein. J. Phys. Chem. B 1998, 102, 3586-3616.
14. Momany, F. A.; Rone, R. Validation of the general-purpose Quanta3.2/ CHARMM force-field J. Comput. Chem. 1992, 13, 888-890.
15. Pattabiraman, N.; Levitt, M.; Ferring, T. E.; Langridge, R. Computer graphics in real-time docking with energy calculation and minimization. J. Comput. Chem. 1985, 6, 432-436.
16. Goldberg, D. E. Genetic Algorithms in Search, Optimization and Machine Learning; Addison-Wesley: Reading, MA, 1989.
17. Holland, J. J. Adaptation in Natural and Artificial Systems; MIT Press: Cambridge, MA, 1975.
18. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J.; Meyer, E. F., Jr.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: a computer-based archival file for macromolecular structures. J. Mol. Biol. 1977, 112, 535-542.
19. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
20. Nar, H.; Bauer, M.; Schmid. A.; Stassen, J. M.; Wienen, W.; Priepke, H. W.; Kauffmann, I. K.; Ries, U. J.; Hauel N. H. Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors. Structure 2001, 9. 29-37.
21. Davies, T. G.; Bentley, J.; Arris, C. E.; Boyle, F. T.; Curtin, N. J.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Jewsbury, P.; Johnson, L. N.; Mesguiche, V.; Newell, D. R.; Noble, M. E.; Tucker, J. A.; Wang, L.; Whitfield H. J. Structurebased design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct Biol. 2002, 9, 745-749.
22. Hong, L.; Zhang, X. J.; Foundling, S.; Hartsuck, J. A.; Tang, J. Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs. FEES Lett. 1991.420, 11-16.
23. Hong, L.; Zhang, X. J.; Hartsuck, J. A.; Tang, J. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci. 2000, 9, 1898-1904.
24. Lam, P. Y.; Jadhav, P.; Eyermann, C.; Hodge, C. N.; Ru, Y.; Bacheler, L.; Meek, J.; Otto, M.; Rayner, M.; Wong, Y.; Chang, C. H.; Weber, P.; Jackson, D.; Sharpe, T.; Erickson-Viitanen, S. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 1994, 263, 380-384.
25. Ala, P. J.; Huston, E. E.; Klabe, R. M.; McCabe, D. D.; Duke, J. L.; Rizzo, C. J.; Korant, B. D.; DeLoskey, R. J.; Lam, P. Y.; Hodge, C. N.; Chang C. H. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry 1997, 36, 1573-1580.
26. Wlodawer, A.; Gustchina, A.; Reshetnikova, L.; Lubkowski, J.; Zdanov, J. A.; Hui, K. Y.; Angleton, E. L.; Farmerie, W. G.; Goodenow, M. M.; Bhatt, D.; Zhang, L.; Dunn, B. M. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus. Nat. Struct. Biol. 1995, 2. 480-488.
27. Loll, P. J.; Picot, D.; Garavito, R. M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol. 1995, 2, 637-643.
28. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents. Nature 1996, 384, 644-648.
29. Sichler, K.; Banner, D. W.; D'Arcy, A.; Hopfner, K. P.; Huber, R.; Bode, W.; Kresse, G. B.; Kopetzki, E.; Brandstetter, H. Crystal structures of uninhibited factor VIIa link its cofactor and substrate-assisted activation to specific interactions. J. Mol. Biol. 2002, 522, 591-603.
30. Hopfner, K. P.; Lang, A.; Karcher, A.; Sichler, K.; Kopetzki, E.; Brandstetter, H.; Huber, R.; Bode, W.; Engh, R. A. Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding. Struct. Fold Den. 1999, 7, 989-996.
31. Mather, T.; Oganessyan, V.; Hof, P.; Huber, R.; Foundling, S.; Esmon, C.; Bode W. The 2.8 A crystal structure of Gla-domainless activated protein C. EMBO J. 1996, 5, 6822-6831.
32. Recacha, R.; Costanzo, M. J.; Maryanoff, B. E.; Carson, M.; DeLucas, L.; Chattopadhyay. D. Structure of human alpha-thrombin complexed with RWJ-51438 at 1.7 A: unusual perturbation of the 60A-60I insertion loop. Acta Crystallogr. D Biol. Crystallogr. 2000, 56, 1395-1400.
33. Rawlings, N. D.; Tolle, D. P.; Barren, A. J. MEROPS: the peptidase database. Nucleic Acids Res. 2004, 32 Database issue: D160-164.
34. Estebanez-Perpina, E.; Bayes, A.; Vendrell, J.; Jongsma, M. A.; Bown, D. P.; Gatehouse, J. A.; Huber, R.; Bode, W.; Aviles, F. X.; Reverter, D. Crystal structure of a novel mid-gut procarboxypeptidase from the cotton pest Helicoverpa armigera. J. Mol. Biol. 2001, 313, 629-638.
35. Garcia-Saez, I.; Reverter, D.; Vendrell, J.; Aviles, F. X.; Coll, M. The three-dimensional structure of human procarboxypeptidase A2. Deciphering the basis of the inhibition, activation and intrinsic activity of the zymogen. EMBO J. 1997, 16, 6906-6913.
36. Barbosa-Pereira, P. J.; Segura-Martin, S.; Oliva, B.; Ferrer-Orta, C.; Aviles, F. X.; Coll, M.; Gomis-Ruth, F. X.; Vendrell, J. Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI). J. Mol. Biol. 2002. 321, 537-547.
37. Teplyakov, A.; Polyakov, K.; Obmolova, G.; Strokopytov, B.; Kuranova, I.; Osterman, A.; Grishin, N.; Smulevitch, S.; Zagnitko. O.; Galperina, O.; et al. Crystal structure of carboxypeptidase T from Thermoactinomyces vulgaris. Eur. J. Biochem. 1992, 208, 281-238.
38. Pearson, W. R. Rapid and Sensitive Sequence Comparison with FASTP and FASTA. Methods Enzymol. 1990, 183, 63-98.
39. Bower, M. J.; Cohen, F. E.; Dunbrack, R. L., Jr. Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. J. Mol. Biol. 1997, 267, 1268-1282.
40. Zhao, S.; Goodsell, D. S.; Olson, A. J. Analysis of a data set of paired uncomplexed protein structures: new metrics for side-chain flexibility and model evaluation. Proteins 2001, 43, 271-279.
41. Canutescu, A. A.; Shelenkov, A. A.; Dunbrack, R. L., Jr. A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci. 2003. 12, 2001-2014.
42. Mendes, J.; Nagarajaram, H. A.; Soares, C. M.; Blundell, T. L.; Carrondo, M. A. Incorporating knowledge-based biases into an energy-based side-chain modeling method: application to comparative modeling of protein structure. Biopolymers 2001, 59, 72-86.
43. Milne, G. W.; Nicklaus, M. C.; Driscoll, J. S.; Wang, S.; Zaharevitz, D. National Cancer Institute drug information system 3D database J. Chem. Inf. Comput. Sci. 1994, 34, 1219-1224.
44. Enyedy, I. J.; Lee, S. L.; Kuo, A. H.; Dickson, R. B.; Lin, C. Y.; Wang, S. Structure-Based Approach for the Discovery of Bis benzamidines as Novel Inhibitors of Matriptase. J. Med. Chem. 2001, 44. 1349-1355.
45. Wang, S.; Milne, G. W.; Van, X.; Posey, I. J.; Nicklaus, M. C.; Graham, L.; Rice, W. G. Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching. J. Med. Chem. 1996, 39, 2047-2054.
46. Panchal, R. G.; Hermone, A. R.; Nguyen, T. L.; Wong, T. Y.; Schwarzenbacher, R.; Schmidt, J.; Lane, D.; McGrath, C.; Turk, B. E.; Burnett, J.; Aman, M. J.; Little, S.; Sausville, E. A.; Zaharevitz, D. W.; Cantley, L, C.,; Liddington, R. C.; Gussio, R.; Bavari, S. Identification of small molecule inhibitors of anthrax lethal factor. Nat. Struct. Mol. Biol. 2004, 11, 67-72.
47. Sirois, S.; Wei, D. Q.; Du, Q.; Chou, K. C. Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points. J. Chem. Inf. Compta. Sci. 2004, 44, 1111-1122.
48. Rastelli, G.; Pacchioni, S.; Sirawaraporn, W.; Sirawaraporn, R.; Parenti, M. D.; Ferrari, A. M. Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors. J. Med. Chem. 2003, 46, 2834-2845.
49. Doman, T. N.; McGovern, S. L.; Witherbee, B. J.; Kasten, T. P.; Kurumbail, R.; Stallings, W. C.; Connolly, D. T.; Shoichet, B. K. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-lB. J. Med. Chem. 2002, 45, 2213-2221.
50. Lee, T.; Le, V. D.; Lim, D.; Lin, Y. C.; Morris, G. M.; Wong, A. L.; Olson, A. J.; Elder, J. H.; Wong, C. H. Development of a new type of protease inhibitors efficacious against FIV and HIV variants. J. Am. Chem. Soc. 1999, 121, 1145-1155.
51. Hosur, M. V.; Bhat, T. N.; Kempf, D. J.; Baldwin, E. T.; Liu, B. S.; Gulnik, S.; Wideburg, N. E.; Norbeck, D. W.; Appell, K.; Erickson, J. W. Influence of stereochemistry on activity and binding modes for C(2) symmetry-based diol inhibitors of HIV-1 protease. J. Am. Chem. Soc. 1994, 116, 847-855.
52. Vermeulen, K.; van Bockstaele, D. R.; Berneman, Z. N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003, 36, 131-149.
53. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Doeter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang. Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4methylphenyl)-3-(trifiuoromethyl)-lH-pyrazol-l-yl]benze nesulfonamide (SC-58635, celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
54. Chan, C. C.; Boyce, S.; Brideau, C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J.; Ford-Hutchinson, A. W.; Forrest, M. J.; Gauthier, J. Y.; Gordon, R.; Gresser, M.; Guay, J.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'Neill, G. P.; Quellet, M.; Patrick, D.; Percival, M. D.; Perrier, H.; Prasit, P.; Rodger, I.; Tagari, P.; Therien, M.; Vickers, P.; Visco, D.; Wang, Z.; Webb, J.; Wong, E.; Xu, L. J.; Young, R. N.; Zamboni, R.; Riendeau, D. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)- furanone] : a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. 1999, 290, 551-560.
55. Bissantz, C.; Bernard, P.; Hibert, M.; Rognan, D. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? Proteins: Struct., Fund., Genet. 2003, 50, 5-25.
56. Johnson, M. A.; Hoog, C.; Pinto, B. M. A novel modeling protocol for protein receptors guided by bound-ligand conformation. Biochemistry 2003, 42, 1842-1853.
57. Evers, A.; Gohlke, H.; Klebe, G. Ligand-supported homology modeling of protein binding-sites using knowledge-based potentials. J. Mol. Biol. 2003, 334, 327-345.
58. Oshiro, C.; Bradley, E. K.; Eksterowicz, J.; Evensen, E.; Lamb, M. L.; Lanctot, J. K.; Putta, S.; Stanton, R.; Grootenhuis, P. D. Performance of 3D-database molecular docking studies into homology models. J. Med. Chem. 2004, 47, 764-767.